Caroline Helwick

1 week ago | ascopost.com | Caroline Helwick

In the phase III KEYNOTE-689 trial, perioperative use of the PD-1 inhibitor pembrolizumab given with standard therapy significantly improved event-free survival in newly diagnosed, previously untreated patients with locally advanced head and neck squamous cell carcinoma, researchers reported at the 2025 American Association for Cancer Research (AACR) Annual Meeting.1 These patients were also significantly more likely to achieve a major pathologic response.

1 month ago | ascopost.com | Caroline Helwick

The outcomes from the phase III ENGOT-OV43/GOG-3036/KEYLYNK-001 trial in advanced BRCA-nonmutated ovarian cancer indicate a statistically significant and clinically meaningful benefit for the PD-1 inhibitor pembrolizumab and chemotherapy, followed by pembrolizumab plus maintenance with the PARP inhibitor olaparib, in newly diagnosed patients.1 In addition, pembrolizumab plus chemotherapy, without olaparib, offered benefit in certain patient subsets not receiving the monoclonal antibody...

1 month ago | ascopost.com | Caroline Helwick

Updated findings from the second planned interim analysis of the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study solidify the PD-1 inhibitor pembrolizumab plus concurrent chemoradiotherapy, followed by pembrolizumab maintenance, as the upfront standard of care for high-risk, locally advanced cervical cancer.

1 month ago | ascopost.com | Caroline Helwick

Today’s oncologists are blessed with an abundance of therapies for HER2-positive early breast cancer, but this comes with the challenge of selecting among them. At the 2025 Miami Breast Cancer Conference, Sara A. Hurvitz, MD, FACP, offered insight on common clinical scenarios.

1 month ago | ascopost.com | Caroline Helwick

The phase III DUO-E study evaluated the addition of the monoclonal antibody durvalumab to chemotherapy, and the benefit of maintenance durvalumab, with and without the PARP inhibitor olaparib, in advanced endometrial cancer. As reported this past year,1 the inclusion of durvalumab reduced the risk of disease progression by 29%; the further addition of olaparib reduced the risk by 45% in the intent-to-treat population.